Category Clinical Trials

6
Nov

Skin Cancer Specialist Dr. Melissa Wilson Joins Sidney Kimmel Cancer Center

The Sidney Kimmel Cancer Center – Jefferson Health (SKCC) welcomes Melissa A. Wilson, MD, PhD, as a new Associate Professor of Medical Oncology. Dr. Wilson treats patients with skin cancers including melanoma, squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma. In addition to her clinical practice, Dr. Wilson leads clinical and translational research …

7
Sep

Sidney Kimmel Cancer Center – Jefferson Health Joins Global Network to Expand Cancer Care Expertise to Patients Worldwide

Newly launched global technology platform, Driver, will connect cancer patients to the best treatments around the world. The Sidney Kimmel Cancer Center – Jefferson Health (SKCC) announces a collaboration with Driver, a first-of-its-kind global technology platform that connects cancer patients to the best treatments, which launched today in the United States and China. Driver’s platform …

25
Jul

Sidney Kimmel Cancer Center Announces ACS Institutional Research Grant Recipients

The Sidney Kimmel Cancer Center – Jefferson Health is pleased to announce the most recent recipients of the American Cancer Society Institutional Research Grants. American Cancer Society Institutional Research Grants are awarded to institutions as block grants to provide seed money for newly independent investigators to initiate research projects. The intent of this support is …

2
Jul

SKCC Investigators Explore New Approaches to Treating Metastatic Colorectal Cancer

A new clinical trial conducted by investigators at the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) and the Lombardi Comprehensive Cancer Center at Georgetown University has generated promising results regarding a novel treatment for metastatic colorectal cancer. The new study, published in the journal Cancer, was led by Jonathan R. Brody, PhD, director of Surgical Research …

24
May

Unique Clinical Trial for Melanoma Patients Begins at Sidney Kimmel Cancer Center

The first patient at the Sidney Kimmel Cancer Center at Jefferson Health recently began receiving treatment as part of a phase II clinical trial studying adjuvant nivolumab. It is a single arm study of nivolumab every 4 weeks for 12 cycles in patients with stage 2b/2c melanoma who have had their melanoma removed and a negative …

20
Mar

Wm. Kevin Kelly, DO, Elected as Co-Chair of NCI Steering Committee

Wm. Kevin Kelly, DO, leader of the Prostate Cancer Program and associate director of Clinical Research at the Sidney Kimmel Cancer Center at Jefferson Health (SKCC), has been elected to serve as medical oncology co-chair on the National Cancer Institute (NCI) Genitourinary Cancers Steering Committee (GUSC). The GUSC addresses the design, prioritization, and evaluation of …

6
Mar

Kevin Kelly, DO, Receives “Director’s Award for Impact” at Member Retreat

Congratulations to Wm. Kevin Kelly, DO, Professor of Medical Oncology and Director of the Division of Solid Tumor Oncology, for receiving the “Director’s Award for Impact” at the recent Sidney Kimmel Cancer Center at Jefferson Health (SKCC) Member Retreat, held at Citizens Bank Park in Philadelphia. Kelly, who is also the leader of the Prostate Cancer …

5
Dec

Researchers Find Breakthroughs in Understanding Genetic Basis of Aggressive Prostate Cancer

The retinoblastoma (RB) susceptibility gene was the first gatekeeper gene discovered for cancer. When it was removed or damaged, cancer thrived. Over the years, researchers have discovered methods that have allowed them to experimentally remove the RB gene in order to study it, but just how the gene’s loss made cancers more aggressive was poorly understood. By studying patient samples, …

23
Mar

Ralph Zinner and Amy Leader Awarded ACT Research Grant from Free to Breathe

The Sidney Kimmel Cancer Center at Jefferson is pleased to announce that Ralph Zinner, MD, and Amy Leader, DrPH, MPH, are the winners of the second Accelerate Clinical Trials (ACT) Research Grant Award from Free to Breathe, an organization devoted to improving the treatment and survival of lung cancer patients.  The ACT grant is a funding …

21
Nov

Dr. Sara Meyer Joins Sidney Kimmel Cancer Center

The Sidney Kimmel Cancer Center at Jefferson is pleased to announce the appointment of Sara Meyer, PhD, as a new assistant professor in the department of Cancer Biology effective November 1, 2016. Previously, Dr. Meyer was a postdoctoral fellow at Cincinnati Children’s Hospital Medical Center. Dr. Meyer received her PhD in Cell and Molecular Cancer …

16
Feb

Jefferson’s Kimmel Cancer Center Establishes Center to Eliminate Cancer Disparities

PHILADELPHIA—In an effort to reduce and eventually eliminate cancer disparities among adults in the Philadelphia region, the Kimmel Cancer Center at Jefferson has established the Center to Eliminate Cancer Disparities. Edith P. Mitchell, M.D., FACP, a medical oncologist at Thomas Jefferson University Hospital and Clinical Professor of Medicine and Medical Oncology in the Department of …

18
Jan

High Dose Vitamin C for Advanced Pancreatic Cancer

By Josh Goldstein, The Daily Dose @Jefferson A small phase I clinical trial at Jefferson University Hospitals of high-dose, intravenous vitamin C in combination with chemotherapy medications show that this treatment is safe and may have promise for patients with advanced pancreatic cancer. The study published in the open access online journal PLoS ONE tested …

16
Jan

New Clinical Trial: Cabazitaxel with Radiation and Hormone Therapy May Improve Prostate Cancer Survival

Jefferson’s Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients. The single-center, open-label, non-randomized Phase I study of weekly Cabazitaxel …

22
Sep

New Half-Match Bone Marrow Transplant Procedure Featured in Philadelphia Inquirer

Neal Flomenberg, M.D., chair of the Department of Medical Oncology at Jefferson and Dolores Grosso, DNP, co-principal investigator of the study, have developed a way to make stem-cell transplants work, even when only half the immune markers are matched. Featured in the “Check Up” section of The Philadelphia Inquirer, this research has major implications. Half-match transplants would triple …

8
Sep

Half-Match Bone Marrow Transplant Procedure Yields Promising Outcomes for Cancer Patients

Half-matched bone marrow or stem cell transplants for blood cancer patients have typically been associated with disappointing clinical outcomes. However, a clinical trial conducted at the Kimmel Cancer Center at Jefferson testing its unique, two-step half-match procedure has produced some promising results: the probability of overall survival was 45 percent in all patients after three years …

22
Mar

Jefferson Clinical Trial: Can a Cholesterol Drug Prevent Colon Cancer?

Thomas Jefferson University has started recruiting patients for a new National Cancer Institute (NCI)-sponsored clinical trial to test whether the cholesterol-reducing drug rosuvastatin is effective in the prevention of recurrent colon cancer. Previous laboratory research and population studies have shown that patients taking statins, the class of drugs that lowers cholesterol, had fewer colon polyps, …

21
Feb

Dr. Leonard Gomella co-chairs ASCO GU in Orlando

Dr. Leonard G. Gomella, chair of the Department of Urology and director of Clinical Affairs at the Kimmel Cancer Center at Jefferson, co-chaired the American Society of Clinical Oncology (ASCO) 2011 Genitourinary (GU) Cancers Symposium meeting in Orlando on Feb. 17 though Feb. 19. The “2011 Genitourinary Cancers Symposium: An Evidence-based Multidisciplinary Approach,” was a …

16
Feb

Shifting a paradigm: A molecular approach to staging colorectal cancer

A quantitative, molecular analysis of lymph nodes in patients deemed colorectal cancer-free was found to be an effective predictor of recurrence, according to a study from researchers at the Kimmel Cancer Center at Jefferson and published online Feb 9. in Clinical Cancer Research. Recurrence occurs in about 25 percent of node-negative patients (pN0), suggesting that …

2
Apr

Dr. Leonard G. Gomella Studies the Effect of Dutasteride on the Risk of Prostate Cancer

Dr. Leonard G. Gomella and colleagues conducted a landmark international randomized, double-blind, placebo-controlled, parallel-group multi-center clinical trial to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease. Over the course of the 4-year study period, dutasteride reduced the risk of …